"Hypoglycaemia is common in EVD, requires repeated correction with intravenous dextrose solutions, and is associated with mortality."

"This initial, exploratory analysis shows early feasibility in using body composition and anthropometric data, that can easily be acquired in community settings, to identify people with dyslipidemia in a normative population."

"The establishment of a stand-alone unit and laboratory dedicated to the care of patients with EVD minimizes the risk of spreading EVD among hospital patients and employees. Risk assessment, instrument validation, and employee training are major components that contribute to the success of establishing this type of laboratory."

"Given its analytical performance and ease of operation, the Piccolo Xpress was transferred to a BSL-2 cabinet in our BSL-3 suite for use in our hospital's diagnostic protocol for providing liver function testing in patients undergoing evaluation for EVD."

"A three-step testing sequence combining a risk factor questionnaire with a point-of-care test [i-STAT, ABL800 FLEX and StatSensor] and confirmatory laboratory testing appears to be a cost-effective use of NHS resources compared with current practice. The risk of contrast causing acute kidney injury to patients with an estimated glomerular filtration rate of < 30 ml/minute/1.73 m² is uncertain. Cost-effectiveness of point-of-care testing [i-STAT, ABL800 FLEX and StatSensor] appears largely driven by the potential of point-of-care tests to minimise delays within the current computed tomography pathway."

This study provides a comprehensive validation of the Abaxis Piccolo Xpress point-of-care analyzer by comparing its performance across all three FDA-approved matrices - whole blood, serum, and plasma - against the Ortho Vitros laboratory standard. By utilizing Bland-Altman bias plots for 14 essential metabolic analytes, the data demonstrates the device's analytical reliability and highlights any specific biases inherent in different specimen types. Ultimately, these findings support the clinical utility of the Piccolo Xpress as a versatile diagnostic tool capable of delivering accurate metabolic profiles in diverse point-of-care settings.

"The Piccolo Xpress chemistry analyzer showed an acceptable analytical performance for precision, linearity and interference from common substances. Increased bias for three analytes in comparison studies could be due to different methodologies."

"The paper ALT test is highly accurate for serum testing, matching the reference method against which it was optimized better than the reference methods matched each other. A systematic difference exists between ALT values in fingerstick and paired serum samples, and can be addressed by application of a correction factor to fingerstick values. Remote reading of this device is feasible."

"The Piccolo xpress Chemistry Analyzer can analyze multiple analytes with a minimal amount of whole blood in a short time. It showed an acceptable performance for precision, linearity and comparison with central laboratory analyzer. It can be useful as a screening tests modality in mobile clinics, ambulances, and field clinics for military use, and for pediatric patients from whom enough sample volume is difficult to obtain."

"The Piccolo Xpress® allows for the delivery of CMP results in a footprint small enough to be stored in a biological safety cabinet, while providing satisfactory performance for the majority of analytes."

"A three-step testing sequence combining a risk factor questionnaire with a point-of-care test [i-STAT, ABL800 FLEX and StatSensor] and confirmatory laboratory testing appears to be a cost-effective use of NHS resources compared with current practice. The risk of contrast causing acute kidney injury to patients with an estimated glomerular filtration rate of < 30 ml/minute/1.73 m² is uncertain. Cost-effectiveness of point-of-care testing [i-STAT, ABL800 FLEX and StatSensor] appears largely driven by the potential of point-of-care tests to minimise delays within the current computed tomography pathway."